Step Therapy Overhaul: $7 Billion in Play
Aetna’s sweeping step therapy expansion, slated for January 2026, has pulled more than $7 billion in annual specialty drug claims under new controls. Regulatory filings and network pharmacy alert letters confirm the scale. The hardest hit? Inflammatory and immunologic drug categories. Internal estimates from RxInfo.ai put the Remicade, Stelara, and Humira biosimilar competition alone at $2.2 billion in redirected claims. Up to 70% of Aetna’s covered lives are now subject to the updated step therapy protocol. The company isn’t subtle about its aim: extract larger rebates by locking in preferred biosimilars and dragging net prices even lower. For context, Aetna’s parent CVS Health reported under $3 billion in drug cost savings from all pharmacy benefit optimizations in 2025. This single policy, depending, of course, on how manufacturers react, could realistically double that figure within two years.
The rule is simple. The aftershock, anything but. Members who started on original biologics now face mandatory trial and failure of at least one preferred biosimilar before they can access higher-cost branded drugs. In theory, exceptions exist for clinical failure or intolerance. In practice, those carve-outs are tightly defined, and reversal rates on appeals hover stubbornly below 5% at the national level. Internally, Aetna actuaries expect 40-50% of new starts in these classes to land on lowest-net-cost products within year one. Rapid shift, no soft landing for legacy brands.
Under Pressure: Manufacturers Shift Strategies
Manufacturers braced for disruption, but not at this pace. Since 2022, the biosimilar market has morphed from a cautious standoff into hand-to-hand combat, all about share and rebate muscle. Aetna’s 2026 step protocol suffocates the old high-list-price incumbents. Drugmakers now dangle market-share guarantees at rebate rates that skim 70% off list in some negotiations. Take one leading infliximab biosimilar: locked in at $1,800 net per infusion, a 67% cut from Remicade’s sticker price, so long as it wins 60% of Aetna’s volume. It’s a forced marriage between procurement teams and manufacturers, but nobody’s pretending it’s romantic.
Power has swung. Five years back, manufacturers orchestrated launches and controlled discounting, reasonably sure PBMs wouldn’t risk disrupting patient care. That’s gone. Today, Aetna leverages deep claims data and sharp utilization controls to warn manufacturers, miss share targets and get “zeroed out.” Behind closed doors, pharma reps admit the pressure is relentless: exclusion threats, retrospective rebate demands, and penalties if even a sliver of share is lost. Specialty pharmacies have to play referee. They see more patient switches, and in some markets, they’re the ones left explaining to providers why a long-used drug suddenly triggers step therapy. There’s grumbling, sometimes outright protest.
Market Moves: Price Drops, Pushback, and Policy Tensions
Biologic makers aren’t sitting still or waiting for access to evaporate. Between February and June 2026, list price cuts across anti-TNF and IL-17 classes ran 12-22%, per RxNews.ai. AbbVie, under siege as Humira lost 19% of Aetna’s covered volume to biosimilars by April, filed for a 15% WAC drop set for Q3, likely a bid to regain favor among plan sponsors. Other brands have dialed up copay support and direct-to-patient outreach, trying to cushion the blow. But in reality, such efforts barely move the needle. Step therapy protocols apply irrespective of copay, and plan designs increasingly shepherd patients toward preferred products, no matter how creative the manufacturer.
And there’s a regulatory undercurrent. Specialty practices logged a 30% spike in step therapy appeals, approvals on exceptions stayed south of 10%. Lawmakers in California and New York have draft bills aimed at curbing the toughest step protocols, citing delayed access for stable patients and a paperwork surge for clinics. It’s hard to say how far these efforts will go. On the ground, the most tangible tension is financial. Employers, watching pharmacy costs overtake even medical inflation, see Aetna’s policy as overdue. New Aetna clients for 2026 project savings of $30 to $45 PMPM in biologics alone, bigger returns than most surgical site-of-care strategies. For a 10,000-life plan, that’s over $4 million per year back into the pool. Data from RxBenefits.ai tracks similar trends for self-insured employers.
Looking Forward: PBM Copycats and the Next Manufacturer Playbook
This isn’t just an Aetna gambit. Word inside UnitedHealthcare’s OptumRx and Cigna’s Express Scripts is that comparable step protocols are on the table for 2027, especially for oncology support meds and rare autoimmune drugs, where biosimilar competition is becoming fierce. If CVS Health proves that 2026 savings materialize without a chaotic provider or patient backlash, expect others to pile on. Manufacturers face a stark new truth: specialty pharma’s leverage has moved, decisively, to payers and PBMs.
Net prices, there’s no sugarcoating it, are moving in only one direction. The next wave of specialty launches, especially in crowded spaces, will have to price aggressively for access right out of the gate. The days of “list high, rebate deep” are dwindling. Step therapy protocols are making it harder for even entrenched brands to hold onto premium status. Pipelines are adjusting. Early market signals show manufacturers planning net launch prices at or under 40% of historical WAC, paired with volume guarantees written into every big contract.
Patients and providers? They’re left reacting to policy changes, not shaping them. The only thing that feels settled is this: step therapy is no longer a boutique cost containment measure, it’s now driving the economics of the entire specialty drug market. Frankly, that might be overdue.
